Filing Analysis
Immuneering Corporation announced its financial results for the quarter ended September 30, 2025, and provided operational updates via a press release.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2025
- Announcement date: November 12, 2025
- The filing includes an earnings press release as Exhibit 99.1
- Company is classified as an emerging growth company
Immuneering Corporation announced a significant dual-track financing involving a public offering of 18.96 million shares and a private placement to Aventis Inc. (a Sanofi subsidiary). The company expects total net proceeds to significantly extend its cash runway into 2029.
🚩 Red Flags
- Significant dilution expected due to the issuance of over 21 million new shares (including option).
- The private placement was contingent upon a 'Qualified Public Offering' meeting specific gross proceeds thresholds ($75M+).
📋 Key Facts
- Public Offering: 18,959,914 shares of Class A common stock at $9.23 per share.
- Underwriters: Leerink Partners LLC and Oppenheimer & Co. Inc.
- Private Placement: Aventis Inc. (Sanofi subsidiary) to purchase 2,708,559 shares at the same price as the public offering.
- Expected Net Proceeds from Offering: ~$164.1 million.
- Expected Net Proceeds from Private Placement: ~$23.3 million.
- Estimated Cash Runway: Sufficient to fund operations into 2029.
- Closing Date: Expected on or about September 26, 2025.
Immuneering Corp entered into a $25.0 million private placement agreement with Aventis Inc. (a Sanofi subsidiary), contingent upon the company successfully closing a separate $75.0 million public offering by September 26, 2025. The filing also includes positive interim Phase 2a clinical data for atebimetinib in pancreatic cancer.
🚩 Red Flags
- High dependency on a massive $75M public offering occurring within days (by Sept 26, 2025) to trigger the private placement.
- Significant restrictions placed on the company by the investor, including a 120-day restriction on negotiating 'Covered Transactions' or strategic sales.
📋 Key Facts
- Entered into a securities purchase agreement with Aventis Inc. (Sanofi subsidiary) for $25.0 million of Class A/B common stock.
- The private placement is contingent upon the closing of a firm commitment public offering of at least $75.0 million by September 26, 2025.
- Aventis Inc. agreed to a 120-day stand-still period regarding strategic transactions and a 1-year lock-up/stand-still on shares.
- Interim Phase 2a data for atebimetinib + mGnP showed 86% OS and 53% PFS at nine months in 34 patients, compared to ~47% OS and ~29% PFS in standard of care.
- The company expects regulatory feedback on Phase 3 plans in Q4 2025 and potential initiation of a pivotal trial by end of 2025.
Immuneering Corporation entered into a $25 million private placement agreement to issue common stock and warrants. The transaction includes significant warrant coverage and requires the company to file a registration statement within 30 days of closing.
🚩 Red Flags
- Significant warrant coverage (approx. 45% per share).
- Pre-funded warrants are immediately exercisable, which can lead to immediate dilution.
- Beneficial ownership limitations (4.99% for warrants, 9.99% for pre-funded) suggest structured investor protection common in distressed or high-risk financing.
📋 Key Facts
- Aggregate gross proceeds: approximately $25.0 million.
- Issuance of 6,329,113 shares of Class A common stock (or pre-funded warrants).
- Issuance of up to 2,848,096 purchase warrants with an exercise price of $5.50 per share.
- Effective purchase price per share/warrant unit: $3.95.
- Closing date expected on or about August 26, 2025.
- Registration statement for resale must be filed within 30 days after closing.
Immuneering Corporation announced its financial results for the quarter ended June 30, 2025. The filing serves as a vehicle to furnish quarterly operational updates and financial performance data via an attached press release.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2025
- Announcement date: August 13, 2025
- The filing includes Exhibit 99.1 containing the full press release of results and operational updates.
- Company is classified as an emerging growth company.
Immuneering Corporation announced positive interim Phase 2a clinical data for atebimetinib in combination with mGnP for first-line pancreatic cancer patients. The results showed an 81% disease control rate and a 39% overall response rate, with the company planning to initiate a pivotal trial in 2026.
🚩 Red Flags
- Clinical stage risk: Results are interim and based on a relatively small patient cohort (n=36).
📋 Key Facts
- Interim data (as of May 26, 2025) for atebimetinib + mGnP arm showed an 81% Disease Control Rate (DCR) among 36 evaluable patients.
- Overall Response Rate (ORR) was reported at 39% (14/36 patients).
- In the 320 mg ITT population (n=34), Overall Survival (OS) was 94% and Progression-Free Survival (PFS) was 72% with a median follow-up of six months.
- Safety profile: Grade ≥ 3 TEAEs were limited to Anemia (18%) and Neutropenia (15%); no Grade 5 events reported.
- Company expects additional Phase 2a data in Q4 2025.
- Planned pivotal trial for pancreatic cancer is slated for 2026, pending regulatory feedback.
Immuneering Corporation held its Annual Meeting of Stockholders on June 13, 2025. The meeting resulted in the successful election of three Class I directors and the ratification of RSM US LLP as the company's independent auditor.
📋 Key Facts
- Annual Meeting held on June 13, 2025.
- Quorum reached with 24,866,430 shares present (approx. 69.1% of outstanding Class A common stock).
- Ann E. Berman elected to the Board of Directors.
- Diana F. Hausman, M.D. elected to the Board of Directors.
- Thomas J. Schall, Ph.D. elected to the Board of Directors.
- Ratification of RSM US LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2025.
Immuneering Corporation announced its financial results for the quarter ended March 31, 2025. The filing serves as a formal announcement of quarterly earnings and operational updates.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2025
- Announcement date: May 5, 2025
- The filing includes an earnings press release furnished as Exhibit 99.1
- Company is classified as an emerging growth company
Immuneering Corp announced its financial results for the quarter and full year ended December 31, 2024. The filing serves as a vehicle to furnish operational updates and quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: Quarter and Full-Year ended December 31, 2024.
- Announcement date: March 20, 2025.
- The filing includes Exhibit 99.1 containing the full press release of results and operational updates.
Immuneering Corp reported positive interim Phase 2a clinical data for its IMM-1-104 therapy in pancreatic cancer patients, showing a 50% overall response rate. Additionally, the company successfully raised $13.7 million through its at-the-market (ATM) equity offering program.
🚩 Red Flags
- Dilution: The utilization of an ATM program indicates ongoing capital needs and potential dilution for existing shareholders.
📋 Key Facts
- Interim Phase 2a data for IMM-1-104 + mFFX in first-line pancreatic cancer: 50% overall response rate (ORR) based on 6 evaluable patients (3 partial responses, 3 stable disease).
- Safety profile of IMM-1-104 with mFFX was reported as generally well tolerated.
- Raised $13.7 million in net proceeds via at-the-market equity offering program as of January 2025.
Immuneering Corporation announced updated interim clinical data for its IMM-1-104 and IMM-6-415 programs, showing positive disease control rates and safety profiles in various pancreatic cancer and solid tumor trials. The company also provided guidance on upcoming data readouts expected in Q2 2025.
📋 Key Facts
- IMM-1-104 + mGnP (Pancreatic): 86% disease control rate (DCR) and 43% overall response rate (ORR) in 7 evaluable patients as of Dec 5, 2024.
- IMM-1-104 + mFFX (Pancreatic): 100% target tumor shrinkage/disease control in 4/4 evaluable patients.
- IMM-1-104 Monotherapy (Second-line Pancreatic): 11 of 21 patients achieved disease control; one partial response with 67% reduction.
- IMM-6-415 Phase 1: Reported significant PD inhibition (up to 77%) and favorable PK levels in 17 evaluable patients as of Dec 23, 2024.
- Safety Profile: IMM-1-104 reported mostly Grade 1/2 adverse events; no Grade 4 or 5 TEAEs observed in the mGnP subset. IMM-6-415 showed no dose-limiting toxicities or serious adverse events.
Immuneering Corporation announced its financial results for the quarter ended September 30, 2024. The filing serves as a formal announcement of operational updates and quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2024
- Announcement date: November 13, 2024
- The filing includes a press release (Exhibit 99.1) detailing financial results and operational updates.
- Company is classified as an 'emerging growth company'.
This 8-K/A filing is an amendment to a previous report, announcing the appointment of Dr. Thomas J. Schall to the Company's Compensation Committee, effective October 1, 2024.
📋 Key Facts
- Dr. Thomas J. Schall was originally elected to the Board as a Class I director on March 11, 2024.
- Effective October 1, 2024, Dr. Schall was appointed to the Compensation Committee of the Board.
- The appointment was made upon the recommendation of the Nominating and Corporate Governance Committee.
Immuneering Corporation announced positive initial clinical response data for its IMM-1-104 combination therapy in first-line pancreatic cancer. The data shows an 80% disease control rate and a 40% overall response rate among the first five patients.
🚩 Red Flags
- Small sample size (n=5) makes the efficacy data highly preliminary and subject to volatility.
📋 Key Facts
- Initial data from 5 patients treated with IMM-1-104 + modified gemcitabine/nab-paclitaxel in pancreatic cancer.
- Achieved an initial 80% Disease Control Rate (DCR) and a 40% Overall Response Rate (ORR).
- Clinical outcomes: 1 Complete Response, 1 Partial Response (unconfirmed), 2 Stable Disease, 1 Equivocal Progressive Disease.
- All five patients remained on treatment as of September 12, 2024.
- DSMB approved enrolling additional patients in the 320mg oral dosing arm.
- Additional data for IMM-1-104 and IMM-6-415 expected by year-end 2024.
Immuneering Corporation announced its financial results for the quarter ended June 30, 2024, and provided operational updates via a press release.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2024
- Announcement date: August 6, 2024
- The filing contains results of operations and financial condition under Item 2.02.
Immuneering Corporation held its Annual Meeting of Stockholders on June 12, 2024. The meeting resulted in the election of two Class III directors and the ratification of RSM US LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on June 12, 2024.
- Quorum represented approximately 69.5% of outstanding Class A common stock (20,606,257 shares).
- Robert J. Carpenter elected as Class III director.
- Benjamin J. Zeskind elected as Class III director.
- Ratification of RSM US LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024.
Immuneering Corp announced the repricing of certain stock options for employees and non-employee service providers to an exercise price of $3.01 per share. The move is intended to incentivize retention without increasing dilution or cash compensation.
🚩 Red Flags
- Option repricing is often viewed as a signal that the company's stock price has significantly underperformed, making previous incentives worthless to employees.
- Potential conflict of interest/optics issue regarding compensation adjustments for service providers and staff during periods of low share price.
📋 Key Facts
- Effective Date: May 21, 2024
- Eligible options had an original exercise price greater than $3.01 per share.
- New exercise price for Eligible Options: $3.01 per share.
- The new price is approximately two times the closing trading price on the Effective Date.
- A 'Retention Period' exists until June 30, 2025; if exercised before this date, the original (higher) exercise price applies unless specific conditions (change of control or termination without cause/death/disability) are met.
- CEO Benjamin Zeskind and CSO Brett Hall were explicitly excluded from the repricing.
Immuneering Corporation announced its financial results for the quarter ended March 31, 2024, and provided operational updates via a press release.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2024
- Announcement date: May 7, 2024
- The filing includes results of operations and financial condition under Item 2.02.
Immuneering Corporation announced the appointment of Dr. Thomas J. Schall to its Board of Directors and reported positive topline Phase 1 safety and proof-of-concept data for its IMM-1-104 clinical candidate.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Appointed Thomas J. Schall, Ph.D. as a Class I Director on March 11, 2024.
- First patient dosed in the Phase 2a portion of the IMM-1-104 clinical trial for advanced RAS-mutant solid tumors.
- Phase 2a portion aims to enroll approximately 150 patients across up to 20 US clinical sites.
- Phase 1 data (as of Feb 20, 2024) showed IMM-1-104 was well-tolerated with no grade 4 treatment-related adverse events (TRAEs).
- Observed 53% of patients had ≥ 1 target lesion(s) regress in the Phase 1 portion.
- Proof of concept demonstrated 90%+ pERK inhibition for 2.7 hours at a 320 mg dose.
Immuneering Corporation announced its financial results for the quarter and full year ended December 31, 2023, alongside operational updates. The filing serves as a formal notice of the release of these earnings results via an attached press release.
📋 Key Facts
- Financial results released for the quarter and full-year ended December 31, 2023.
- The company provided operational updates alongside financial data.
- Filing date: March 1, 2024.
Immuneering Corporation has adopted amended and restated bylaws effective February 1, 2024. The changes primarily focus on compliance with new SEC universal proxy rules and enhancing procedural mechanics for stockholder nominations.
📋 Key Facts
- Board of Directors adopted amendments to the Company's Amended and Restated Bylaws on February 1, 2024.
- Amendments address SEC universal proxy rules (Rule 14a-19) regarding proxy solicitation by non-board nominees.
- New requirements for stockholder nominations include additional background information and disclosures regarding ownership and material agreements.
- A requirement was added that stockholders soliciting proxies must use a proxy card color other than white.